LabCorp Resolution ctDx Lung Assay

LabCorp has launched the Resolution ctDx Lung assay for patients with non-small cell lung cancer (NSCLC). The test will be run by Resolution Biosciences and detects actionable mutations associated with the disease in a standard blood sample. The firm said the test can provide valuable information to help select the most effective targeted treatments for individual patients. In addition, LabCorp noted that the test is covered by Medicare.